RVMDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMDW
Revolution Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$182.15+4.19 (+2.35%)
Close on Oct 19, 2026
- Market cap
- $38.41B
- P/E (TTM)
- –
- Dividend yield
- –
Revolution Medicines, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -58.1%
Financial strength
- Current ratio
- 11.38
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 230.3%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 14.74
- Dividend yield
- –